The use of exosome carrier to augmentation of Helicobacter pylori infection treatment.

Abstract

Stem Cell Investig 2020;7:23 | http://dx.doi.org/10.21037/sci-2020-028 Helicobacter pylori (H. pylori) is a stomach pathogen that half of the world’s population is conjectured to be tangled in this gram-negative bacterium (1). It is generally obtained in babyhood, and when left untreated commonly continues for the host’s lifetime (2). The early role of H. pylori in the peptic lesion and gastric cancer expansion was established and admitted by the medic community as recently as the 1980s (3,4). To retain the chronic form of infection the bacterium changes tissue morphology and physiology by the transfer of virulence factors like the CagA, VacA toxins, and γ-glutamyltranspeptidase (GGT) enzyme that result in worsening the pathology of the infection (5,6). General standard eradication strategies use two antibiotics and an acid-suppressing drug, now usually completed with bismuth (3). Although the usage of antibiotics throughout the previous decades and improved health conditions has forcefully decreased H. pylori prevalence, infection frequency remains high on a universal measure (7). A longsome antibiotic therapy against H. pylori infection is growing to start to fail, and innovative strategies towards treatment need to be taken (8). In addition to the concerns on diminishing eradication efficiencies during the burdensome treatment with several broad-spectrum antibiotics, there are the health concerns about adverse impacts on the commensal microbiota (9,10). Especially in the treatment of pediatric H. pylori, the synchronic loss of the gut flora by extensive antibiotics is a major challenge. Furthermore, reducing eradication effectiveness, off-target impacts of lengthy broad-spectrum antibiotic therapies, and the desire of a more regular eradication in asymptomatic H. pylori carriers to reduce gastric cancer occurrence spur a search for finding a smarter remedial option to deliver of antibiotic in local (3,11). A direct drug delivery is an effective approach to increase efficacy therapy helicobacter pylori infection. Recently, considerable research has been focused on exosomes as nanocarriers for direct drug delivery. Exosomes are nanosized (30–150 nm) lipid bilayer particles of endosomal source. They belong to the extracellular vesicles (EVs) that secrete by multiple cell types and involve in cell-cell communication or intracellular signaling (12). The membrane building of exosome makes them have an innate potency to fuse with the membrane of the acceptor organelle or plasma cell, and play a major role in the transport of bioactive cellular cargos such as proteins, lipids, and RNAs at a neighbor or distant cell (13). Indeed, exosomes as safe and natural drug delivery carriers able to trip in extracellular fluids and deliver various therapeutic agents to target cells with high efficiency (14). Furthermore, the ideal direct drug delivery carrier should be able to site-specific delivery of loaded therapeutics, avoid premature degradation through the body’s immune defense system and controlled release of it upon selective stimuli (15). In addition to these properties, exosomes have manifested many advantages in biocompatibility terms and reduced clearance levels in comparison with other direct drug delivery carrier. Moreover, they show slight long-term accumulation in various organs or tissue, with synchronous low systemic toxicity (16,17). In recent years, exosomebased drug (synthetic or biological molecules) delivery strategies have been used in a wide variety of disorders including cancer, various infections, neurodegenerative and cardiovascular disorders (18). For example, the exosomes derived from EL-4 cells have been used to deliver curcumin and via enhancing of anti-inflammatory effects of curcumin Editorial Commentary